| Name | MGC Pharmaceuticals Limited NPV (DI) |
|---|---|
| Epic | MXC |
| Isin | AU000000MXC6 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 22.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £723.03 | Debt ratio | n/a |
| Shares in issue | 3,286.48 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -213.07 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -65 | 52-week high / low | 18.00p / 550.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | MGC Pharmaceuticals Limited NPV (DI) |
|---|---|
| Address | 1202 Hay Stree, West Perth, Australia, WA 6005 |
| Telephone | +61 (8)6382 3390 |
| Website | http://www.mgcpharma.com.au/ |
| Director | Position |
|---|---|
| Mr Nativ Segev | Non-Executive Director |
| Mr Layton Mills | Non-Executive Director |
| Mr Brett Mitchell | Non-Executive Chairman |
| Mr Roby Zomer | Managing Director and CEO |
| Dr Stephen Parker | Senior Independent Director |
| Dr Ross Walker | Independent Non-Executive Director |
| Assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 30/06/22 | 30/06/21 | 30/06/20 |
| Intangible asssets and goodwill | 5.38 | 7.05 | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 15.24 | 14.75 | 4.7 |
| Inventory / work in progress | 2.22 | 0.87 | 0.4 |
| Trade and other receivables | 3.35 | 3.1 | 0.59 |
| Cash and equivalents | 1.79 | 5.51 | 1.87 |
| Other current assets and asset held for resale | n/a | n/a | 0.36 |
| Total of all assets | 22.6 | 24.24 | 7.93 |
| Liabilities $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 7.02 | 6.07 | 2.97 |
| Long term liabilities | 4.53 | 4.34 | 1.87 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 11.54 | 10.41 | 4.83 |
| Net assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 11.06 | 13.83 | 3.09 |
| Equity $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 97.44 | 84.51 | 60.15 |
| Minority interests | -0.56 | -0.01 | -0.01 |
| Retained earnings | -94.76 | -78 | -62.13 |
| Share premium account | 7.74 | 7.49 | n/a |
| Total equity | 11.06 | 13.83 | 3.09 |
| Income $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -16.95 | -15.79 | -18.65 |
| Pre-tax profit | -17.14 | -15.9 | -18.77 |